0
million ESRD patients worldwide
0
%
CAGR for ESRD in next 5 years
0
billion U.S. Medicare spending on ESRD
0
%
of Medicare budget for 1% (ESRD patients) of general patient population
[Source: Jenny Blair, Holding Out for Home Hemodialisys: Still-Modest Market Promises Bigger Growth, Medtech Insight; 15-Sep-2017]

Worldwide 3.3 million people suffer from end-stage renal disease. This number continues to grow due to an aging population and the increase of conditions such as diabetes, hypertension, and obesity.

The market seeks an effective, easy-to-use dialysis solution for improved treatment benefits and reduced health care costs.

According to Markets and Markets, the global dialysis market was $61 billion in 2013, with a CAGR of 6.2% in the next five years.

Globally, there is a gradual shift toward home-based dialysis therapies. This shift is attributed to (1) increasing costs associated with in-center hemodialysis (equipment, staff, and procedure-related clinical complications) and (2) clinical evidence demonstrating the value of peritoneal dialysis (PD) in improving quality of life.

PD is gaining traction in the US and other countries. Increasing at a significant 8.2% CAGR, peritoneal dialysis is the fastest-growing segment in this market, expected to reach $5.4 billion in 2018.

The liberDi system aims to answer the needs of all stakeholders by providing

  • a safe and easy-to-use system for the majority of ESRD patients
  • treatment at a lower cost for hospitals and healthcare systems
  • a great improvement in quality of life for patients and their caregivers

The liberDi system presents the technological solution to increase the number of people with ESRD to choose at-home PD as their treatment modality.